Therapeutic potential of monteplase in acute myocardial infarction

被引：4

作者：

Inoue T. ^{[1
,4
]}

Nishiki R. ^{[2
]}

Kageyama M. ^{[3
]}

Node K. ^{[1
]}

机构：

[1] Department of Cardiovascular and Renal Medicine, Saga University, Faculty of Medicine, Saga

[2] Pharmaceuticals Department, Eisai Co. Ltd., Tokyo

[3] Product Planning Division, Eisai Co. Ltd., Tokyo

[4] Department of Cardiovascular and Renal Medicine, Saga University, Faculty of Medicine, Saga 849-8801

来源：

American Journal of Cardiovascular Drugs | 2005年 / 5卷 / 4期

关键词：

Percutaneous Coronary Intervention; Acute Myocardial Infarction; Brain Natriuretic Peptide; Alteplase; Primary Percutaneous Coronary Intervention;

D O I：

10.2165/00129784-200505040-00002

中图分类号：

学科分类号：

摘要：

Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：225 / 231

页数：6

共 33 条

[1]

Randomised trial of intravenous streptokinase, oral aspirin or both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 2, 8607, pp. 349-360, (1988)

[2]

White H.D., Norris R.M., Brown M.A., Et al., Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction, N Engl J Med, 317, 14, pp. 850-855, (1987)

[3]

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet, 1, 8478, pp. 397-402, (1986)

[4]

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II a results, JAMA, 260, 19, pp. 2849-2858, (1988)

[5]

Simoons M.L., Arnold A.E., Betriu A., Et al., Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty, Lancet, 1, 8579, pp. 197-203, (1988)

[6]

Zijlstra F., De Boer M.J., Hoorntje J.C., Et al., A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction, N Engl J Med, 328, 10, pp. 680-684, (1993)

[7]

O'Neill W.W., Weintraub R., Grines C.L., Et al., A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction, Circulation, 86, 6, pp. 1710-1717, (1992)

[8]

Widimsky P., Groch L., Zelizko M., Et al., Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: The Prague study, Eur Heart J, 21, 10, pp. 823-831, (2000)

[9]

Topol E.J., Califf R.M., George B.S., Et al., A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction, N Engl J Med, 317, 10, pp. 581-588, (1987)

[10]

Ross A.M., Coyne K.S., Reiner J.S., Et al., A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial, J Am Coll Cardiol, 34, 7, pp. 1954-1962, (1999)

← 1 2 3 4 →